Cell Therapy

In the rapidly evolving landscape of synthetic biology, the ability to control engineered cells with the same precision we use to adjust a thermostat is becoming a reality. Ivan Kairatov, a biopharma expert with a deep background in research and development, joins us to discuss a groundbreaking

The biopharmaceutical industry reached a significant milestone this week as Waypoint Bio secured twenty million dollars in seed funding to accelerate the development of next-generation chimeric antigen receptor T-cell therapies that utilize advanced artificial intelligence models. This investment

The ability to monitor the precise journey of therapeutic cells within the human body has remained an elusive goal for decades, often forcing clinicians to rely on indirect markers to guess whether a treatment has reached its intended target. This lack of visibility represents a significant hurdle

The persistent challenge of treating non-small cell lung cancer lies not in the absence of potent therapeutic agents but in the inherent difficulty of delivering these treatments exclusively to malignant cells while preserving the integrity of surrounding healthy pulmonary tissue. Modern oncology

The landscape of regenerative medicine has reached a critical juncture where the promise of engineered immune cells must finally overcome the logistical barriers of the ivory tower. For over a decade, chimeric antigen receptor T-cell therapies represented a double-edged sword: they offered

The moment a physician can decode the specific genetic vulnerabilities of a tumor marks the beginning of a profound shift in how the medical community approaches the most aggressive forms of human disease. At the 2026 American Society for Clinical Oncology Annual Meeting, the focus transitioned